Educational Webinar with Dr. Matthias Orth
Abstract
Testing for abnormal immunoglobulins was based previously on serum electrophoresis and immunofixation only. In the last years, however, free light chain (FLC) testing in serum became one important pillar in the diagnosis and monitoring of Multiple Myeloma and related disorders such as Amyloidosis, most of these diseases occurring in older patients. In particular, the ratio of κ FLCs to λ FLCs became pivotal in the diagnosis, monitoring, and rule-out of patients with suspected myeloma. The challenge of this serum testing is the heterogeneity of free light chains and other methodical issues of testing which challenge in particular FLC tests based on turbidimetry and nephelometry.
The other challenges arise from the accumulation of FLC in serum due to the impaired excretion of FLC in patients with altered renal function – and renal function will decrease with age physiologically. Since elevated FLC will damage the kidneys, the establishment of reference ranges is challenging, and adequate reference ranges are necessary to obtain good discrimination between patients and normal (healthy) subjects. This webinar will describe the laboratory tests currently used and will suggest methods to establish reference ranges that allow the optimized use of FLC assays.
Speaker’s Biography
Matthias Orth received his training in Clinical Pathology at the universities of Freiburg and Magdeburg (Germany). From 1994-1997 he worked as a postdoctoral fellow at the Gladstone Institutes (GICD) of the University of San Francisco (UCSF). After his employment at the Free University Berlin and at Leipzig University, he became director of the Institute of Laboratory Medicine at Marienhospital Stuttgart in 2004. He is lecturer at the University of Heidelberg, Medical Faculty of Mannheim. He is active in the German Society of Laboratory Medicine as well as in IFCC, with a research focus on laboratory management. Very recently, he became chair of the Task Force Direct to Consumer testing of EFLM (TF-DTCT).
2005 Multiple sclerosis consensus criteria includes CSF IgG oligoclonal bands.
2017 Mc Donald Criteria for multiple sclerosis diagnosis includes CSF IgG oligoclonal bands.
Educational Webinar with Prof. Giovanni PALLADINI, PhD
The perfect match for screening hemoglobin disorders in newborns
Article from Jean Deenmamode, IFCC CDT working group chair in CLI magazine.
Find out what the role of a Chemistry Production Manager is.
Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL
Educational Webinar with David G. Grenache, PhD, D(ABCC)
Chief Scientific Officer, TriCore Reference Laboratories
Educational Workshop with Pr Giovanni Palladini
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
Educational Webinar with Dr. Matthias Orth from University of Heidelberg at University Hospital Mannheim.
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
CDT is a sensitive and specific marker of chronic alcohol abuse, used in several contexts and notably including forensic settings, industries, clinical applications.
Educational Webinar with Dr. Julien GUILLEMAUD
Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results depending on the method of analysis used. Therefore, it is important to know the limitations of the method used for HbA1c determination.
The EurA1c trial, organized yearly, investigates the performance of HbA1c assays across countries and manufacturers.
EAN 2022
Sebia booth: #510
Algorithm for congenital and acquired von Willebrand disease includes Hydragel vWF multimer analysis.
Evaluation of Sebia’s isoelectrofocusing kit for A1AT with HYDRASYS.
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
Improve your lab performance by optimizing your Sebia solutions.
This article assesses the performances of the different manufacturers and technologies (HPLC and CE) for Hb A2 measurement using both International Reference Reagent for HbA2 (WHO IRR 89/666) and analysis of three whole blood specimens over a range of HbA2, distributed to 56 laboratories located in 14 different countries.
Find out what the role of a R&D Manager is.
GCSCD 2022
Sebia booth: #9
Educational Webinar with Jason EYRE
Educational Webinar Dr. Cornelia L. Harteveld from Leiden University Medical Center
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
Educational Webinar with Dr. Rachel WHEELER
Multimer analysis to improve von Willebrand disease classification with Hydragel vWF multimer Sebia.
Educational Webinar with Dr. Ilaria Ferrarotti
International Congress on Autoimmunity 2022
Booth: #23
IMS 2024
Sebia booth: #1134
ISTH 2022
Sebia booth: #1037
ISTH 2023
Sebia booth: #2005
IFCC CDT-Working Group standardized the CDT measurement.
Interview between Sebia and M. Jean Deenmamode, CDT IFCC Working Group Chair
Medlab Dubai 2022
Sebia booth: #Z5.H10
Educational Webinar with Dr. Mark Zaydman from Washington University School of Medicine in St. Louis, MO
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.
This special Issue related to newborn screening for Sickle Cell disease and other hemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD.
Find out what the role of a Knowledge Center Advisor is.
Educational Webinar with Dr. Cas WEYKAMP
Educational Webinar with Katie Thoren, PhD, Memorial Sloan Kettering Cancer Center
Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians.
In this report, we evaluated the use of the capillary electrophoresis (CE) migration position in the CAPILLARYS 2 CE instrument.
Educational Webinar with Juliana A. Silva
Educational Webinar with Dr Nadia Maria Porpiglia
The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity
IFCC Standardisation of the Sebia CDT measurement on CAPILLARYS 3 TERA.
Understand your needs and constraints to provide you with the most suitable and integrated solution.
Educational Webinar with Dr. Annette BOWYER, Lead Biomedical Scientist
This article reminds the reader of the importance of detecting the Hb variants when measuring HbA1c for the labs and clinicians to better interpret the results and to ensure optimal management of the diabetic patient.
Educational Webinar with M. Jean Deenmamode, IFCC Working Group Chair
Educational Webinar Pr Simone Scarlata
TIAFT 2023
Sebia booth: #8
Understand in 2 minutes how capillary electrophoresis works, and why it gives such high and clear resolution in lab testing.
There are three types of von Willebrand Disease. In this leaflet, different cases from congenital and acquired VWD are presented.
Correlation of von Willebrand factor with the severity of COVID-9 progression.
Dieser Abschnitt enthält Informationen, die für die weite Verbreitung bestimmt sind. Sie können daher Produktdetails oder Informationen enthalten, die in Ihrem Land nicht verfügbar oder gültig sind.
Bitte kontaktieren Sie Ihren regionalen Sebia-Kundenvertreter. Informationen für medizinische Fachkräfte.
Lesen Sie die Anweisungen in den Reagenz-Packungsbeilagen und Instrumentenhandbüchern sorgfältig durch